Key Asthma Abstracts From AAAAI 2023

Anju T. Peters, MD, MSci


March 20, 2023

Dr Anju Peters from Northwestern University reports on key data on asthma from the American Academy of Allergy, Asthma & Immunology annual meeting.

Dr Peters begins by discussing the CHRONICLE study, which examined biologic outcomes among US patients with severe asthma and allergic diseases who were treated by subspecialists. It concluded that exacerbation reductions were more pronounced in those with higher total IgE levels and those treated with non-omalizumab biologics.

Next, Dr Peters reports on a study of the impact of systemic corticosteroid exposure on healthcare resource utilization (HRU). Patients treated with systemic corticosteroids had more comorbidities and were more likely to be on controller medications and use rescue inhalers. They also had higher all-cause and asthma-related HRU and healthcare costs at baseline.

Dr Peters then discusses the RAPID registry, which studied baseline characteristics of patients with asthma treated with dupilumab in a real-world setting; it concluded that these patients are mostly female and overweight, and they have impaired lung function and decreased quality of life.

Finally, Dr Peters looks at racial and ethnic disparities in treatment of uncontrolled disease among patients with severe, persistent asthma. A study showed that medication escalation for uncontrolled disease was suboptimal for all patients and was worse among non-White patients, and it concluded that efforts are needed to close care gaps and reduce health inequities.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.